Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Virginie Zimmer

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Gene Therapy|July 8, 2020
Maximizing lentiviral vector gene transfer in the CNSMorgane Humbel, Mergim Ramosaj, Virginie Zimmer, et al.
Experimental Neurology|August 5, 2018
Therapeutic efficacy of regulable GDNF expression for Huntington's and Parkinson's disease by a high-induction, background-free "GeneSwitch" vectorShi Cheng, Julia Tereshchenko, Virginie Zimmer, et al.
Molecular Therapy. Methods & Clinical Development|June 13, 2017
Preclinical Evaluation of a Lentiviral Vector for Huntingtin SilencingKarine Cambon, Virginie Zimmer, Sylvain Martineau, et al.
Journal for Immunotherapy of Cancer|August 28, 2020
Guillain-Barré syndrome after adoptive cell therapy with tumor-infiltrating lymphocytesAngela Orcurto, Andreas Hottinger, Benita Wolf, et al.
Cell Reports|September 21, 2017
The Self-Inactivating KamiCas9 System for the Editing of CNS Disease GenesNicolas Merienne, Gabriel Vachey, Lucie de Longprez, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Gene Therapy|July 8, 2020
Maximizing lentiviral vector gene transfer in the CNSMorgane Humbel, Mergim Ramosaj, Virginie Zimmer, et al.
Experimental Neurology|August 5, 2018
Therapeutic efficacy of regulable GDNF expression for Huntington's and Parkinson's disease by a high-induction, background-free "GeneSwitch" vectorShi Cheng, Julia Tereshchenko, Virginie Zimmer, et al.
Molecular Therapy. Methods & Clinical Development|June 13, 2017
Preclinical Evaluation of a Lentiviral Vector for Huntingtin SilencingKarine Cambon, Virginie Zimmer, Sylvain Martineau, et al.
Journal for Immunotherapy of Cancer|August 28, 2020
Guillain-Barré syndrome after adoptive cell therapy with tumor-infiltrating lymphocytesAngela Orcurto, Andreas Hottinger, Benita Wolf, et al.
Cell Reports|September 21, 2017
The Self-Inactivating KamiCas9 System for the Editing of CNS Disease GenesNicolas Merienne, Gabriel Vachey, Lucie de Longprez, et al.
Pageof 1